粪便免疫化学检测(FIT)与结肠镜在筛查及息肉切除术后监测中的比较:一项诊断准确性与成本效果研究
本研究在英格兰肠癌筛查计划中纳入息肉切除术后中危患者,比较每年FIT监测与3年一次结肠镜监测的诊断准确性和成本效果。结果显示,以40 µg/g血红蛋白阈值行FIT监测,3年程序对结直肠癌和进展期腺瘤的敏感性分别为59%和33%,可减少71%的结肠镜检查并显著降低成本,但可能漏诊30%-40%的结直肠癌和40%-70%的进展期腺瘤。
要点
- 在40 µg/g阈值下,FIT监测3年程序对结直肠癌敏感性59%,对进展期腺瘤敏感性33%。
- 以FIT替代3年一次结肠镜监测可减少71%的结肠镜检查并显著降低成本。
- FIT监测可能漏诊30%-40%的结直肠癌和40%-70%的进展期腺瘤。
核心结论
- 以每年FIT替代中危患者3年一次结肠镜监测可减少71%的结肠镜检查并显著降低成本,但可能漏诊30%-40%的结直肠癌和40%-70%的进展期腺瘤。
研究设计与样本
- 在英格兰肠癌筛查计划(BCSP)中招募推荐3年一次监测的中危患者(60-72岁),招募时间为2012年1月至2013年12月。
- 在息肉切除术后第1、2、3年提供FIT,纳入同意参加并返还第1年FIT的受邀者。
- 第1年或第2年FIT阳性(血红蛋白≥40 µg/g)者提前接受结肠镜,其余所有人在第3年接受结肠镜。
- 评估结直肠癌和进展期腺瘤(AAs)的诊断准确性时考虑多次检测和不同阈值,并计算结肠镜监测相对于FIT监测每额外检出1例AA和1例CRC的增量成本。
主要发现
- 74%(5938/8009)的受邀者因在第1年参与而被纳入研究,其中97%在第2年和第3年返还FIT。
- 3年累积阳性率在40 µg/g血红蛋白阈值下为13%,在10 µg/g阈值下为29%。
- 29例参与者诊断为结直肠癌,446例诊断为进展期腺瘤。
- 3年程序对结直肠癌和进展期腺瘤的敏感性在40 µg/g阈值下分别为59%和33%,在10 µg/g阈值下分别为72%和57%。
- 结肠镜监测相对于FIT(40 µg/g)监测每额外检出1例进展期腺瘤和1例结直肠癌的增量成本分别为7354英镑和180778英镑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The English Bowel Cancer Screening Programme (BCSP) recommends 3 yearly colonoscopy surveillance for patients at intermediate risk of colorectal cancer (CRC) postpolypectomy (those with three to four small adenomas or one ≥10 mm). We investigated whether faecal immunochemical tests (FITs) could reduce surveillance burden on patients and endoscopy services. DESIGN: Intermediate-risk patients (60-72 years) recommended 3 yearly surveillance were recruited within the BCSP (January 2012-December 2013). FITs were offered at 1, 2 and 3 years postpolypectomy. Invitees consenting and returning a year 1 FIT were included. Participants testing positive (haemoglobin ≥40 µg/g) at years one or two were offered colonoscopy early; all others were offered colonoscopy at 3 years. Diagnostic accuracy for CRC and advanced adenomas (AAs) was estimated considering multiple tests and thresholds. We calculated incremental costs per additional AA and CRC detected by colonoscopy versus FIT surveillance. RESULTS: 74% (5938/8009) of invitees were included in our study having participated at year 1. Of these, 97% returned FITs at years 2 and 3. Three-year cumulative positivity was 13% at the 40 µg/g haemoglobin threshold and 29% at 10 µg/g. 29 participants were diagnosed with CRC and 446 with AAs. Three-year programme sensitivities for CRC and AAs were, respectively, 59% and 33% at 40 µg/g, and 72% and 57% at 10 µg/g. Incremental costs per additional AA and CRC detected by colonoscopy versus FIT (40 µg/g) surveillance were £7354 and £180 778, respectively. CONCLUSIONS: Replacing 3 yearly colonoscopy surveillance in intermediate-risk patients with annual FIT could reduce colonoscopies by 71%, significantly cut costs but could miss 30%-40% of CRCs and 40%-70% of AAs. TRIAL REGISTRATION NUMBER: ISRCTN18040196; Results.
引用
- Cross AJ, Wooldrage K, Robbins EC, et al. Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study. Gut. 2018. PMID: 30538097. doi:10.1136/gutjnl-2018-317297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。